Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

BERG Announces Presentation Of Multiple Interrogative Biology Platform And Outputs At AACR

BERG, a clinical-stage biotech that employs artificial intelligence (AI) to research diseases and develop innovative treatments, announced five presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from June 22- 24, 2020.

Two presentations feature outputs of the BERG Interrogative Biology platform. One focuses on BERG’s Interrogative Biology discovered oncology target BPM 42522, its lead molecule, and mechanism of action leading to its anti-cancer properties. The other highlights validation of the BERG pan-cancer model by an independent study (Behan FM et al., (Nature, 2019 Apr 10). Three other presentations demonstrate the translational impact from current collaborations with institutions including BIDMC/HarvardStanford University and Uniformed Services University of the Health Sciencesalong with Walter Reed National Military Medical Center.

Recommended AI News: AI-Powered Agricultural Robots: A Revolution In Affordable Ultra-Precision, Says IDTechEx

Related Posts
1 of 40,387

“We are making significant advances with BERG’s Interrogative Biology platform, by partnering with several thought leaders in the field of oncology at the upcoming AACR meeting,” said Dr. Niven R. Narain, BERG Co-founder, President and Chief Executive Officer. “This week, we will present the preliminary results of a lead molecule that modulates BPM 42522, as a direct result from BERG’s platform as well.  None of this would be possible without the continued support of our partners around the world.”

Recommended AI News: IntoPIX Releases The FastTICO-XS SDK V1.2.4 For NVIDIA GPU

“BERG’s pioneering work in analyzing large molecular datasets with Bayesian Artificial Intelligence for identification of therapeutic targets with high translational potential, clearly illustrates the impact of our work in improving drug discovery as well as  the success rates of our developments,” said Professor Vikas P. Sukhatme, M.D., Sc.D., Dean of the Emory School of Medicine, Chief Academic Officer of Emory Healthcare, and a member of BERG’s Scientific Advisory Board.

Recommended AI News: Jeff Loeb Rejoins Chief Outsiders To Help SaaS, Cloud And Technology Companies Build Growth Engines And Accelerate Revenue

Comments are closed, but trackbacks and pingbacks are open.